Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
June 12, 2026
June 12, 2026
BOSTON, Massachusetts, June 12 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
*
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2a inhibitor, as adjuvant treatment for adult patients with ren . . .
* * *
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
*
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2a inhibitor, as adjuvant treatment for adult patients with ren . . .